167 293

Cited 5 times in

Prevalence of and clinical factors associated with lipoatrophy in HIV-infected Koreans receiving highly active antiretroviral therapy

DC FieldValueLanguage
dc.contributor.author최준용-
dc.contributor.author최희경-
dc.contributor.author한상훈-
dc.contributor.author김준명-
dc.contributor.author김창오-
dc.contributor.author백지현-
dc.contributor.author송영구-
dc.contributor.author신소연-
dc.contributor.author이현철-
dc.contributor.author진범식-
dc.contributor.author채윤태-
dc.date.accessioned2015-04-24T16:54:45Z-
dc.date.available2015-04-24T16:54:45Z-
dc.date.issued2009-
dc.identifier.issn0040-8727-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/104406-
dc.description.abstractLipoatrophy is the long-term adverse effects developed in human immunodeficiency virus (HIV)-1-infected subjects receiving highly active antiretroviral therapy (HAART). This cross-sectional study aimed to evaluate the prevalence of and clinical factors associated with lipoatrophy in HIV-infected Koreans receiving HAART for more than 6 months. Lipoatrophy was diagnosed by concordance between physical examination and history taking performed by a single physician. Various covariates were examined, including diabetes mellitus (DM), lipid profiles after HAART, and HAART regimen and duration. Among total 144 patients (6 females and 138 males), 35 patients (24.3%) were diagnosed with lipoatrophy. The prevalence of lipoatrophy was significantly higher in females than that in males [83.3% (5/6) vs. 21.7% (30/138), p = 0.010] and higher in patients with DM than patients without DM [66.7% (4/6 DM) vs. 22.5% (31/138 non-DM), p = 0.030], or in patients with high total cholesterol levels than patients with low total cholesterol levels [31.9% (23/72 patients with high cholesterol) vs. 16.7% (12/72 patients with low cholesterol), p = 0.035]. Moreover, patients with stavudine treatment history (> 12 months) had a higher prevalence of lipoatrophy than patients who never received stavudine [50.0% (15/30) vs. 16.5% (17/103), p < 0.001]. In the multivariate logistic analysis, stavudine treatment for > 12 months (OR, 3.67; p = 0.011) and being female (OR, 24.93; p = 0.009) are independently associated with lipoatrophy. In conclusion, the prevalence of lipoatrophy in HIV-infected Koreans receiving HAART is not uncommon. Limited use of stavudine and regular monitoring are warranted to reduce lipoatrophy-
dc.description.statementOfResponsibilityopen-
dc.format.extent145~153-
dc.relation.isPartOfTOHOKU JOURNAL OF EXPERIMENTAL MEDICINE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAntiretroviral Therapy, Highly Active/adverse effects*-
dc.subject.MESHAsian Continental Ancestry Group-
dc.subject.MESHFemale-
dc.subject.MESHHIV Infections/complications*-
dc.subject.MESHHIV Infections/drug therapy*-
dc.subject.MESHHumans-
dc.subject.MESHLipodystrophy/chemically induced*-
dc.subject.MESHLipodystrophy/complications-
dc.subject.MESHLipodystrophy/diagnosis-
dc.subject.MESHLipodystrophy/epidemiology*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPrevalence-
dc.subject.MESHRegression Analysis-
dc.subject.MESHRepublic of Korea/epidemiology-
dc.titlePrevalence of and clinical factors associated with lipoatrophy in HIV-infected Koreans receiving highly active antiretroviral therapy-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorSang Hoon Han-
dc.contributor.googleauthorBum Sik Chin-
dc.contributor.googleauthorHee Kyoung Choi-
dc.contributor.googleauthorSo Youn Shin-
dc.contributor.googleauthorYun Tae Chae-
dc.contributor.googleauthorJi-Hyeon Baek-
dc.contributor.googleauthorChang Oh Kim-
dc.contributor.googleauthorJun Yong Choi-
dc.contributor.googleauthorYoung Goo Song-
dc.contributor.googleauthorHyun Chul Lee-
dc.contributor.googleauthorJune Myung Kim-
dc.identifier.doi10.1620/tjem.219.145-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA04191-
dc.contributor.localIdA04228-
dc.contributor.localIdA04286-
dc.contributor.localIdA00953-
dc.contributor.localIdA01044-
dc.contributor.localIdA01839-
dc.contributor.localIdA02037-
dc.contributor.localIdA02116-
dc.contributor.localIdA03301-
dc.contributor.localIdA03981-
dc.contributor.localIdA04022-
dc.relation.journalcodeJ02738-
dc.identifier.eissn1349-3329-
dc.identifier.pmid19776532-
dc.subject.keywordLipoatrophy-
dc.subject.keywordHIV-
dc.subject.keywordHighly active antiretroviral therapy-
dc.subject.keywordStavudine-
dc.subject.keywordKorea-
dc.contributor.alternativeNameChoi, Jun Yong-
dc.contributor.alternativeNameChoi, Hee Kyoung-
dc.contributor.alternativeNameHan, Sang Hoon-
dc.contributor.alternativeNameKim, June Myung-
dc.contributor.alternativeNameKim, Chang Oh-
dc.contributor.alternativeNameBaek, Ji Hyeon-
dc.contributor.alternativeNameSong, Young Goo-
dc.contributor.alternativeNameShin, So Youn-
dc.contributor.alternativeNameLee, Hyun Chul-
dc.contributor.alternativeNameChin, Bum Sik-
dc.contributor.alternativeNameChae, Yun Tae-
dc.contributor.affiliatedAuthorChoi, Jun Yong-
dc.contributor.affiliatedAuthorChoi, Hee Kyoung-
dc.contributor.affiliatedAuthorHan, Sang Hoon-
dc.contributor.affiliatedAuthorKim, June Myung-
dc.contributor.affiliatedAuthorKim, Chang Oh-
dc.contributor.affiliatedAuthorBaek, Ji Hyeon-
dc.contributor.affiliatedAuthorSong, Young Goo-
dc.contributor.affiliatedAuthorShin, So Youn-
dc.contributor.affiliatedAuthorLee, Hyun Chul-
dc.contributor.affiliatedAuthorChin, Bum Sik-
dc.contributor.affiliatedAuthorChae, Yun Tae-
dc.citation.volume219-
dc.citation.number2-
dc.citation.startPage145-
dc.citation.endPage153-
dc.identifier.bibliographicCitationTOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, Vol.219(2) : 145-153, 2009-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.